|
業績
|
| |
【英文原著論文（2016-2022）】
2022年
- Kawauchi D, Ohno M, Miyakita Y, Takahashi M,
Yanagisawa S, Omura T, Yoshida A, Kubo Y, Igaki
H, Ichimura K, Narita Y. “Early Diagnosis
and Surgical Intervention Within 3 Weeks From
Symptom Onset Are Associated With Prolonged
Survival of Patients With Glioblastoma.”
Neurosurgery. 2022 Aug 15. doi:
10.1227/neu.0000000000002096. Online ahead of
print. PMID: 35951724
- Sonehara K, Kimura Y, Nakano Y, Ozawa T,
Takahashi M, Suzuki K, Fujii T, Matsushita Y,
Tomiyama A, Kishikawa T, Yamamoto K, Naito T,
Suzuki T, Yamaguchi S, Miwa T, Sasaki H,
Kitagawa M, Ohe N, Fukai J, Ogiwara H, Kawamura
A, Miyawaki S, Matsuda F, Kiyokawa N,
Ichimura K, Nishikawa R, Okada Y,
Terashima K. “A common deletion at BAK1 reduces
enhancer activity and confers risk of
intracranial germ cell tumors.” Nat Commun. 2022
Aug 2;13(1):4478. doi:
10.1038/s41467-022-32005-9. PMID: 35918310
- Satomi K, Yoshida A, Matsushita Y, Sugino H,
Fujimoto K, Honda-Kitahara M, Takahashi M, Ohno
M, Miyakita Y, Narita Y, Yatabe Y, Shibahara J,
Ichimura K. “Clinical application of a
highly sensitive digital PCR assay to detect a
small fraction of IDH1 R132H-mutant alleles in
diffuse gliomas.” Brain Tumor Pathol. 2022 Jul
29. doi: 10.1007/s10014-022-00442-5. Online
ahead of print. PMID: 35902443
- Kurozumi K, Fujii K, Washio K, Ishida J, Otani
Y, Sudo T, Tahara M, Ichimura K, Ennishi
D, Date I. “Response to entrectinib in a
malignant glioneuronal tumor with ARHGEF2-NTRK
fusion.” Neurooncol Adv. 2022 Jun
13;4(1):vdac094. doi: 10.1093/noajnl/vdac094.
eCollection 2022 Jan-Dec. PMID: 35821677
- Natsume A, Arakawa Y, Narita Y, Sugiyama K, Hata
N, Muragaki Y, Shinojima N, Kumabe T, Saito R,
Motomura K, Mineharu Y, Miyakita Y, Yamasaki F,
Matsushita Y, Ichimura K, Ito K,
Tachibana M, Kakurai Y, Okamoto N, Asahi T,
Nishijima S, Yamaguchi T, Tsubouchi H, Nakamura
H, Nishikawa R. “The first-in-human phase I
study of a brain penetrant mutant IDH1 inhibitor
DS-1001 in patients with recurrent or
progressive IDH1-mutant gliomas.” Neuro
Oncol. 2022 Jun 20:noac155. doi:
10.1093/neuonc/noac155. Online ahead of print.
PMID: 35722822
- Satomi K, Ohno M, Kubo T, Honda-Kitahara M,
Matsushita Y, Ichimura K, Narita Y,
Ichikawa H, Yoshida A. “Central nervous system
sarcoma with ATXN1::DUX4 fusion expands the
concept of CIC-rearranged sarcoma.”
Genes Chromosomes Cancer. 2022
Jun 17. doi: 10.1002/gcc.23080. Online ahead of
print. PMID: 35715887
- Handa H, Shibahara I, Nakano Y, Inukai M, Sato
S, Hide T, Hirato J, Yoshioka T, Ichimura
K, Kumabe T. “Molecular analyses of
rosette-forming glioneuronal tumor of the
midbrain tegmentum: A report of two cases and a
review of the FGFR1 status in unusual tumor
locations.” Surg Neurol Int.
2022 May 20;13:213. doi: 10.25259/SNI_55_2022.
eCollection 2022. PMID: 35673672
- Omura T, Takahashi M, Ohno M, Miyakita Y,
Yanagisawa S, Tamura Y, Kikuchi M, Kawauchi D,
Nakano T, Hosoya T, Igaki H, Satomi K, Yoshida
A, Sunami K, Hirata M, Shimoi T, Sudo K, Okuma
HS, Yonemori K, Suzuki H, Ichimura K,
Narita Y. “Clinical Application of Comprehensive
Genomic Profiling Tests for Diffuse Gliomas.”
Cancers (Basel). 2022 May
16;14(10):2454. doi: 10.3390/cancers14102454.
PMID:35626060
- Takami H, Nakamura H, Ichimura K,
Nishikawa R. “Still divergent but on the way to
convergence: clinical practice of CNS germ cell
tumors in Europe and North America from the
perspectives of the East.” Neurooncol
Adv. 2022 Apr 22;4(1):vdac061. doi:
10.1093/noajnl/vdac061. eCollection 2022
Jan-Dec. PMID: 35611272
- Yamazaki A, Arai Y, Fukuoka K, Nakano Y, Hama N,
Nakata S, Makino K, Kuroda JI, Shinojima N,
Mukasa A, Mikami Y, Ichimura K, Shibata
T, Yokoo H, Nobusawa S. “Diffusely infiltrating
glioma with CREBBP-BCORL1 fusion showing
overexpression of not only BCORL1 but BCOR: A
case report.” Brain Tumor
Pathol. 2022 May 21. doi:
10.1007/s10014-022-00435-4. Online ahead of
print. PMID: 35596897
- Ohno M, Miyakita Y, Takahashi M, Yanagisawa S,
Tamura Y, Kawauchi D, Kikuchi M, Igaki H,
Yoshida A, Satomi K, Matsushita Y, Ichimura
K, Narita Y. “Assessment of therapeutic
outcome and role of reirradiation in patients
with radiation-induced glioma.” Radiat
Oncol. 2022 May 3;17(1):85. doi:
10.1186/s13014-022-02054-x. PMID: 35505351
- Kojima N, Arai Y, Satomi K, Kubo T, Matsushita
Y, Mori T, Matsushita H, Ushijima T, Yatabe Y,
Shibata T, Yonemori K, Ichimura K,
Ichikawa H, Kawai A, Yoshida A. “Co-expression
of ERG and CD31 in a subset of CIC-rearranged
sarcoma: a potential diagnostic pitfall.”
Mod Pathol. 2022 Apr 19. doi:
10.1038/s41379-022-01078-8. Online ahead of
print. PMID: 35440765
- Hosoya T, Takahashi M, Honda-Kitahara M,
Miyakita Y, Ohno M, Yanagisawa S, Omura T,
Kawauchi D, Tamura Y, Kikuchi M, Nakano T,
Yoshida A, Igaki H, Matsushita Y, Ichimura
K, Narita Y. “MGMT gene promoter
methylation by pyrosequencing method correlates
volumetric response and neurological status in
IDH wild-type glioblastomas.” J
Neurooncol. 2022 Apr 10. doi:
10.1007/s11060-022-03999-5. Online ahead of
print. PMID: 35397757
- Sasame J, Ikegaya N, Kawazu M, Natsumeda M,
Hayashi T, Isoda M, Satomi K, Tomiyama A, Oshima
A, Honma H, Miyake Y, Takabayashi K, Nakamura T,
Ueno T, Matsushita Y, Iwashita H, Kanemaru Y,
Murata H, Ryo A, Terashima K, Yamanaka S, Fujii
Y, Mano H, Komori T, Ichimura K, Cahill
DP, Wakimoto H, Yamamoto T, Tateishi K. “HSP90
inhibition overcomes resistance to molecular
targeted therapy in BRAFV600E mutant high-grade
glioma.” Clin Cancer Res. 2022
Mar 28:clincanres.3622.2021. doi:
10.1158/1078-0432.CCR-21-3622. Online ahead of
print. PMID: 35344043
- Takami H, Graffeo CS, Perry A, Giannini C,
Nakazato Y, Saito N, Matsutani M, Nishikawa R,
Ichimura K, Daniels DJ. “Roles of Tumor
Markers in Central Nervous System Germ Cell
Tumors Revisited with Histopathology-Proven
Cases in a Large International Cohort.” Cancers
(Basel). 2022 Feb 15;14(4):979. doi:
10.3390/cancers14040979. PMID: 35205726
- Yanagi M, Fukuoka K, Mori M, Arakawa Y,
Matsushita Y, Hibiya Y, Tanami Y, Ichimura
K, Hirato J, Nakazawa A, Kurihara J, Koh
K. “Prognostic Implication of DNA Methylation
Signature in Atypical Choroid Plexus Papilloma
With Intracranial Dissemination.” J Pediatr
Hematol Oncol. 2022 May 1;44(4):e844-e848. doi:
10.1097/MPH.0000000000002428. Epub 2022 Feb 18.
PMID: 35180763
- Takami H, Elzawahry A, Mamatjan Y, Fukushima S,
Fukuoka K, Suzuki T, Yanagisawa T, Matsushita Y,
Nakamura T, Satomi K, Tanaka S, Mukasa A, Saito
N, Kanamori M, Kumabe T, Tominaga T, Kobayashi
K, Nagane M, Iuchi T, Tamura K, Maehara T,
Sugiyama K, Yoshimoto K, Sakai K, Nonaka M, Asai
A, Yokogami K, Takeshima H, Narita Y, Shibui S,
Nakazato Y, Hama N, Totoki Y, Kato M, Shibata T,
Nishikawa R, Matsutani M, Ichimura K;
Intracranial Germ Cell Tumor Genome Analysis
Consortium (the iGCT Consortium). “Transcriptome
and Methylome Analysis of CNS Germ Cell Tumor
Finds its Cell-of-Origin in Embryogenesis and
Reveals Shared Similarities with Testicular
Counterparts.” Neuro Oncol. 2022 Aug
1;24(8):1246-1258. doi: 10.1093/neuonc/noac021.
PMID: 35137206
- Yoshida A, Satomi K, Kobayashi E, Ryo E,
Matsushita Y, Narita Y, Ichimura K, Kawai
A, Mori T. “Soft tissue sarcoma with MN1-BEND2
fusion: a case report and comparison with
astroblastoma.” Genes Chromosomes Cancer. 2022
Jan 30. doi: 10.1002/gcc.23028. Online ahead of
print. PMID: 35094441
- Uchida E, Sasaki A, Shirahata M, Suzuki T,
Adachi JI, Mishima K, Yasuda M, Fujimaki T,
Ichimura K, Nishikawa R. “Role of
proliferative marker index and KBTBD4 mutation
in the pathological diagnosis of pineal
parenchymal tumors.” Brain Tumor Pathol. 2022
Jan 9. doi: 10.1007/s10014-021-00421-2. Online
ahead of print. PMID: 35000018
- Kawauchi D, Ohno M, Honda-Kitahara M, Miyakita
Y, Takahashi M, Yanagisawa S, Tamura Y, Kikuchi
M, Ichimura K, Narita Y. “The clinical
characteristics and outcomes of incidentally
discovered glioblastoma.” J Neurooncol. 2022
Feb;156(3):551-557. doi:
10.1007/s11060-021-03931-3. Epub 2022 Jan 5.
PMID: 34985720
- Nakano T, Fujimoto K, Tomiyama A, Takahashi M,
Achiha T, Arita H, Kawauchi D, Yasukawa M,
Masutomi K, Kondo A, Narita Y, Maehara T,
Ichimura K. “Eribulin prolongs survival
in an orthotopic xenograft mouse model of
malignant meningioma.” Cancer Sci. 2022
Feb;113(2):697-708. doi: 10.1111/cas.15221. Epub
2021 Dec 8. PMID: 34839570Cancer Sci. 2021 Nov
27. doi: 10.1111/cas.15221. Online ahead of
print. PMID: 34839570
- Satomi K, Takami H, Fukushima S, Yamashita S,
Matsushita Y, Nakazato Y, Suzuki T, Tanaka S,
Mukasa A, Saito N, Kanamori M, Kumabe T,
Tominaga T, Kobayashi K, Nagane M, Iuchi T,
Yoshimoto K, Tamura K, Maehara T, Sakai K,
Sugiyama K, Yokogami K, Takeshima H, Nonaka M,
Asai A, Ushijima T, Matsutani M, Nishikawa R,
Ichimura K. “12p gain is predominantly
observed in non-germinomatous germ cell tumors
and identifies an unfavorable subgroup of
central nervous system germ cell tumors.” Neuro
Oncol. 2022 May 4;24(5):834-846. doi:
10.1093/neuonc/noab246. PMID: 34698864Neuro
Oncol. 2021 Oct 26:noab246. doi:
10.1093/neuonc/noab246. Online ahead of print.
PMID: 34698864
2021年
- Arakawa A, Sasaki K, Mineharu Y, Uto M, Mizowaki
T, Mizusawa J, Sekino Y, Ono T, Aoyama H, Satomi
K, Ichimura K, Kinoshita M, Ohno M, Ito
Y, Nishikawa R, Fukuda H, Nishimura Y, Narita Y
and Brain Tumor Study Group and Radiation
Therapy Study Group of the Japan Clinical
Oncology Group. “A randomized phase III study of
short-course radiotherapy combined with
Temozolomide in elderly patients with newly
diagnosed glioblastoma; Japan clinical oncology
group study JCOG1910 (AgedGlio-PIII).” BMC
Cancer (2021) 21:1105
https://doi.org/10.1186/s12885-021-08834-0
- Ohno M, Hayashi Y, Aikawa H, Hayashi M, Miyakita
Y, Takahashi M, Matsushita Y, Yoshida A, Satomi
K, Ichimura K, Hamada A, Narita Y.
“Tissue 2-Hydroxyglutarate and Preoperative
Seizures in Patients with Diffuse Gliomas.”
Neurology. 2021 Nov 23;97(21):e2114-e2123. doi:
10.1212/WNL.0000000000012893. Epub 2021 Oct 5.
PMID: 34610989
- Yamamuro S, Takahashi M, Satomi K, Sasaki N,
Kobayashi T, Uchida E, Kawauchi D, Nakano T,
Fujii T, Narita Y, Kondo A, Wada K, Yoshino A,
Ichimura K, Tomiyama A. “CCNU and ACNU
exert efficient antitumor effects against
glioblastoma models with acquired temozolomide
resistance.” Cancer Sci. 2021 112(11):4736-4747.
doi: 10.1111/cas.15141. PMID: 34536314
- Takami H, Satomi K, Fukuoka K, Fukushima S,
Matsushita Y, Yamasaki K, Nakamura T, Tanaka S,
Mukasa A, Saito N, Suzuki T, Yanagisawa T,
Nakamura H, Sugiyama K, Tamura K, Maehara T,
Nakada M, Nonaka M, Asai A, Yokogami K,
Takeshima H, Iuchi T, Kanemura Y, Kobayashi K,
Nagane M, Kurozumi K, Yoshimoto K, Matsuda M,
Matsumura A, Hirose Y, Tokuyama T, Kumabe T,
Narita Y, Shibui S, Nakazato Y, Nishikawa R,
Matsutani M, Ichimura K. “Low tumor cell
content predicts favorable prognosis in
germinoma patients.” Neurooncol Adv. 2021 Aug
10;3(1):vdab110. doi: 10.1093/noajnl/vdab110.
eCollection 2021 Jan-Dec. PMID: 34549182
- Yamagishi Y, Sasaki N, Nakano Y, Matushita Y,
Omura T, Shimizu S, Saito K, Kobayashi K, Narita
Y, Kondo A, Shiokawa Y, Nagane M, Ichimura
K. “Liquid biopsy of cerebrospinal fluid
for MYD88 L265P mutation is useful for diagnosis
of central nervous system lymphoma.” Cancer Sci.
2021 112(11):4702-4710. doi: 10.1111/cas.15133.
PMID: 34523186
- Yoshida A, Arai Y, Satomi K, Kubo T, Ryo E,
Matsushita Y, Hama N, Sudo K, Komiyama M, Yatabe
Y, Shibata T, Ichikawa H, Ichimura K,
Kawai A, Mori T. “Identification of novel SSX1
fusions in synovial sarcoma.” Mod Pathol. 2022
Feb;35(2):228-239. doi:
10.1038/s41379-021-00910-x. Epub 2021 Sep 9.
PMID: 34504309
- Sievers P, Henneken SC, Blume C, Sill M,
Schrimpf D, Stichel D, Okonechnikov K, Reuss DE,
Benzel J, Maaß KK, Kool M, Sturm D, Zheng
T, Ghasemi DR, Kohlhof-Meinecke P, Cruz O,
Suñol M, Lavarino C, Ruf V, Boldt HB,
Pagès M, Pouget C, Schweizer L,
Kranendonk MEG, Akhtar N, Bunkowski S,
Stadelmann C, Schüller U, Mueller WC,
Dohmen H, Acker T, Harter PN, Mawrin C,
Beschorner R, Brandner S, Snuderl M, Abdullaev
Z, Aldape K, Gilbert MR, Armstrong TS, Ellison
DW, Capper D, Ichimura K, Reifenberger G,
Grundy RG, Jabado N, Krskova L, Zapotocky M,
Vicha A, Varlet P, Wesseling P, Rutkowski S,
Korshunov A, Wick W, Pfister SM, Jones DTW, von
Deimling A, Pajtler KW, Sahm F. “Recurrent
fusions in PLAGL1 define a distinct subset of
pediatric-type supratentorial neuroepithelial
tumors.” Acta Neuropathol. 2021
Nov;142(5):827-839. doi:
10.1007/s00401-021-02356-6. Epub 2021 Aug 5.
PMID: 34355256
- Kanamori M, Takami H, Suzuki T, Tominaga T,
Kurihara J, Tanaka S, Hatazaki S, Nagane M,
Matsuda M, Yoshino A, Natsumeda M, Yamaoka M,
Kagawa N, Akiyama Y, Fukai J, Negoto T,
Shibahara I, Tanaka K, Inoue A, Mase M, Tomita
T, Kuga D, Kijima N, Fukami T, Nakahara Y,
Natsume A, Yoshimoto K, Keino D, Tokuyama T,
Asano K, Ujifuku K, Abe H, Nakada M, Matsuda KI,
Arakawa Y, Ikeda N, Narita Y, Shinojima N, Kambe
A, Nonaka M, Izumoto S, Kawanishi Y, Kanaya K,
Nomura S, Nakajima K, Yamamoto S, Terashima K,
Ichimura K, Nishikawa R. “Necessity for
craniospinal irradiation of germinoma with
positive cytology without spinal lesion on MR
imaging-A controversy.” Neurooncol Adv. 2021 Jun
25;3(1):vdab086. doi: 10.1093/noajnl/vdab086.
eCollection 2021 Jan-Dec. PMID: 34355256
- Tsutsui T, Arakawa Y, Makino Y, Kataoka H,
Mineharu Y, Naito K, Minamiguchi S, Hirose T,
Nobusawa S, Nakano Y, Ichimura K, Haga H,
Miyamoto S. “Spinal cord astroblastoma with
EWSR1-BEND2 fusion classified as HGNET-MN1 by
methylation classification: a case report.”
Brain Tumor Pathol. 2021 Oct;38(4):283-289. doi:
10.1007/s10014-021-00412-3. Epub 2021 Jul 27.
PMID: 34313881
- Kawaguchi RK, Takahashi M, Miyake M, Kinoshita
M, Takahashi S, Ichimura K, Hamamoto R,
Narita Y, Sese J. “Assessing Versatile Machine
Learning Models for Glioma Radiogenomic Studies
across Hospitals.” Cancers (Basel). 2021 Jul
19;13(14):3611. doi: 10.3390/cancers13143611.
PMID: 34298824
- Takami H, Graffeo CS, Perry A, Ohno M, Ishida J,
Giannini C, Narita Y, Nakazato Y, Saito N,
Nishikawa R, Matsutani M, Ichimura K,
Daniels DJ. “Histopathology and prognosis of
germ cell tumors metastatic to brain: cohort
study.” J Neurooncol. 2021 Aug;154(1):121-130.
doi: 10.1007/s11060-021-03810-x. Epub 2021 Jul
16. PMID: 34272633
- Nakano Y, Satomi K, Okada K, Gotoh M, Ushiama M,
Sakamoto H, Yoshida T, Kunihiro N, Hira K,
Fukushima H, Inoue T, Hirato J, Ichimura
K, Hara J. “Malignant brain tumor in an
infant showing histopathological features of
yolk sac tumor but genetic and epigenetic
features of AT/RT.” Pediatr Blood Cancer. 2021
Sep;68(9):e29192. doi: 10.1002/pbc.29192. Epub
2021 Jun 29. PMID: 34185381
- Fujimoto K, Arita H, Satomi K, Yamasaki K,
Matsushita Y, Nakamura T, Miyakita Y, Umehara T,
Kobayashi K, Tamura K, Tanaka S, Higuchi F,
Okita Y, Kanemura Y, Fukai J, Sakamoto D, Uda T,
Machida R, Kuchiba A, Maehara T, Nagane M,
Nishikawa R, Suzuki H, Shibuya M, Komori T,
Narita Y, Ichimura K. “TERT promoter
mutation status is necessary and sufficient to
diagnose IDH-wildtype diffuse astrocytic glioma
with molecular features of glioblastoma.” Acta
Neuropathol. 2021 Aug;142(2):323-338. doi:
10.1007/s00401-021-02337-9. Epub 2021 Jun 20. t.
PMID: 34148105
- Hiraki T, Fukuoka K, Mori M, Arakawa Y,
Matsushita Y, Hibiya Y, Honda S, Kobayashi M,
Tanami Y, Ichimura K, Hirato J, Kurihara
J, Nakazawa A, Koh K. “Application of
Genome-Wide DNA Methylation Analysis to
Differentiate a Case of Radiation-Induced
Glioblastoma From Late-Relapsed
Medulloblastoma.” J Neuropathol Exp Neurol. 2021
Jun 4;80(6):552-557. doi: 10.1093/jnen/nlab043.
PMID: 33990838
- Yonezawa H, Ohno M, Igaki H, Miyakita Y,
Takahashi M, Tamura Y, Shima S, Matsushita Y,
Ichimura K, Narita Y. “Outcomes of
salvage fractionated re-irradiation combined
with bevacizumab for recurrent high-grade
gliomas that progressed after bevacizumab
treatment.” Jpn J Clin Oncol. 2021 Jul
1;51(7):1028-1035. doi: 10.1093/jjco/hyab063.
PMID: 33959771
- Takahashi S, Takahashi M, Kinoshita M, Miyake M,
Kawaguchi R, Shinojima N, Mukasa A, Saito K,
Nagane M, Otani R, Higuchi F, Tanaka S, Hata N,
Tamura K, Tateishi K, Nishikawa R, Arita H,
Nonaka M, Uda T, Fukai J, Okita Y, Tsuyuguchi N,
Kanemura Y, Kobayashi K, Sese J, Ichimura
K, Narita Y, Hamamoto R. “Fine-Tuning
Approach for Segmentation of Gliomas in Brain
Magnetic Resonance Images with a Machine
Learning Method to Normalize Image Differences
among Facilities.” Cancers (Basel). 2021 Mar
19;13(6):1415. doi: 10.3390/cancers13061415.
PMID: 33808802
- Kawauchi D, Takahashi M, Satomi K, Yamamuro S,
Kobayashi T, Uchida E, Honda-Kitahara M, Narita
Y, Iwadate Y, Ichimura K, Tomiyama A.
“The ALK inhibitors, alectinib and ceritinib,
induce ALK-independent and STAT3-dependent
glioblastoma cell death.” Cancer Sci. 2021 Mar
16. doi: 10.1111/cas.14885. Online ahead of
print. PMID: 33728771
- Ozawa T, Kaneko S, Szulzewsky F, Qiao Z,
Takadera M, Narita Y, Kondo T, Holland EC,
Hamamoto R, Ichimura K. “C11orf95-RELA
fusion drives aberrant gene expression through
the unique epigenetic regulation for ependymoma
formation.” Acta Neuropathol Commun. 2021 Mar
8;9(1):36. doi: 10.1186/s40478-021-01135-4.
PMID: 33685520
- Tomomasa R, Arai Y, Kawabata-Iwakawa R, Fukuoka
K, Nakano Y, Hama N, Nakata S, Suzuki N, Ishi Y,
Tanaka S, Takahashi JA, Yuba Y, Shiota M,
Natsume A, Kurimoto M, Shiba Y, Aoki M,
Nabeshima K, Enomoto T, Inoue T, Fujimura J,
Kondo A, Yao T, Okura N, Hirose T, Sasaki A,
Nishiyama M, Ichimura K, Shibata T,
Hirato J, Yokoo H, Nobusawa S. “Ependymoma-like
tumor with mesenchymal differentiation harboring
C11orf95-NCOA1/2 or -RELA fusion: A hitherto
unclassified tumor related to ependymoma.” Brain
Pathol. 2021 Feb 12 31:e12943. doi:
10.1111/bpa.12943. PMID: 33576087
2020年
- Kinoshita M, Arita H, Takahashi M, Uda T, Fukai
J, Ishibashi K, Kijima N, Hirayama R, Sakai M,
Arisawa A, Takahashi H, Nakanishi K, Kagawa N,
Ichimura K, Kanemura Y, Narita Y, Kishima
H. “Impact of Inversion Time for FLAIR
Acquisition on the T2-FLAIR Mismatch
Detectability for IDH-Mutant, Non-CODEL
Astrocytomas.” Front Oncol. 2021 Jan
14;10:596448. doi: 10.3389/fonc.2020.596448.
eCollection 2020. PMID: 33520709
- Miyake Y, Fujii K, Nakamaura T, Ikegaya N,
Matsushita Y, Gobayashi Y, Iwashita H, Udaka N,
Kumagai J, Murata H, Takemoto Y, Yamanaka S,
Ichimura K, Tateishi K, Yamamoto T.
“IDH-Mutant Astrocytoma With Chromosome 19q13
Deletion Manifesting as an
Oligodendroglioma-Like Morphology.” J
Neuropathol Exp Neurol. 2021 Jan 12:nlaa161.
doi: 10.1093/jnen/nlaa161. Online ahead of
print. PMID: 33432322
- Mitani Y, Fukuoka K, Mori M, Arakawa Y,
Matsushita Y, Hibiya Y, Honda S, Kobayashi M,
Tanami Y, Kanemura Y, Ichimura K,
Nakazawa A, Kurihara J, Koh K. “Clinical
Aggressiveness of TP53-Wild Type Sonic Hedgehog
Medulloblastoma With MYCN Amplification,
Chromosome 17p Loss, and Chromothripsis.” J
Neuropathol Exp Neurol. 2021 Jan
20;80(2):205-207. doi: 10.1093/jnen/nlaa124.
Online ahead of print. PMID: 33367701
- Kobayashi T, Miyazaki M, Sasaki N, Yamamuro S,
Uchida E, Kawauchi D, Takahashi M, Otsuka Y,
Kumagai K, Takeuchi S, Toyooka T, Otani N, Wada
K, Narita Y, Yamaguchi H, Muragaki Y, Kawamata
T, Mori K, Ichimura K, Tomiyama A.
“Enhanced Malignant Phenotypes of Glioblastoma
Cells Surviving NPe6-Mediated Photodynamic
Therapy are Regulated via ERK1/2 Activation.”
Cancers (Basel). 2020 Dec 4;12(12):E3641. doi:
10.3390/cancers12123641. PMID: 33291680
- Arita H, Matsushita Y, Machida R, Yamasaki K,
Hata N, Ohno M, Yamaguchi S, Sasayama T, Tanaka
S, Higuchi F, Iuchi T, Saito K, Kanamori M,
Matsuda KI, Miyake Y, Tamura K, Tamai S,
Nakamura T, Uda T, Okita Y, Fukai J, Sakamoto D,
Hattori Y, Pareira ES, Hatae R, Ishi Y, Miyakita
Y, Tanaka K, Takayanagi S, Otani R, Sakaida T,
Kobayashi K, Saito R, Kurozumi K, Shofuda T,
Nonaka M, Suzuki H, Shibuya M, Komori T, Sasaki
H, Mizoguchi M, Kishima H, Nakada M, Sonoda Y,
Tominaga T, Nagane M, Nishikawa R, Kanemura Y,
Kuchiba A, Narita Y, Ichimura K. “TERT
promoter mutation confers favorable prognosis
regardless of 1p/19q status in adult diffuse
gliomas with IDH1/2 mutations.” Acta Neuropathol
Commun. 2020 Nov 23;8(1):201. doi:
10.1186/s40478-020-01078-2. PMID: 33228806
- Takadera M, Satomi K, Szulzewsky F, Cimino PJ,
Holland EC, Yamamoto T, Ichimura K, Ozawa
T. “Phenotypic characterization with somatic
genome editing and gene transfer reveals the
diverse oncogenicity of ependymoma fusion
genes.” Acta Neuropathol Commun. 2020 Nov
23;8(1):203. doi: 10.1186/s40478-020-01080-8.
PMID: 33228790
- Tamai S, Nakano Y, Kinoshita M, Sabit H,
Nobusawa S, Arai Y, Hama N, Totoki Y, Shibata T,
Ichimura K, Nakada M. “Ependymoma with
C11orf95-MAML2 fusion: presenting with granular
cell and ganglion cell features.” Brain Tumor
Pathol. 2021 Jan;38(1):64-70. doi:
10.1007/s10014-020-00388-6. Epub 2020 Nov 22.
PMID: 33221956.
- Satomi K, Ohno M, Matsushita Y, Takahashi M,
Miyakita Y, Narita Y, Ichimura K, Yoshida
A. “Utility of methylthioadenosine phosphorylase
immunohistochemical deficiency as a surrogate
for CDKN2A homozygous deletion in the assessment
of adult-type infiltrating astrocytoma.” Mod
Pathol. 2020 Oct 19. doi:
10.1038/s41379-020-00701-w. Online ahead of
print. PMID: 33077924
- Tateishi K, Miyake Y, Kawazu M, Sasaki N,
Nakamura T, Sasame J, Yoshii Y, Ueno T, Miyake
A, Watanabe J, Matsushita Y, Shiba N, Udaka N,
Ohki K, Fink AL, Tummala SS, Natsumeda M,
Ikegaya N, Nishi M, Ohtake M, Miyazaki R,
Suenaga J, Murata H, Aoki I, Miller JJ, Fujii Y,
Ryo A, Yamanaka S, Mano H, Cahill DP, Wakimoto
H, Chi AS, Batchelor TT, Nagane M, Ichimura
K, Yamamoto T. “A hyperactive
RelA/p65-hexokinase 2 signaling axis drives
primary central nervous system lymphoma” Cancer
Res. 2020 Oct 16 80(23): 5330-5343
:canres.2425.2020. doi:
10.1158/0008-5472.CAN-20-2425. PMID: 33067267
- Nobusawa S, Nakata S, Nakano Y, Kawamura A,
Yoshida M, Tamura A, Hasegawa D, Kosaka Y, Ito
I, Watanabe R, Oishi T, Hayashi N, Ishikawa E,
Sakamoto N, Okura N, Murakami C, Ichimura
K, Hirato J, Yokoo H. “CNS Low-grade
Diffusely Infiltrative Tumors With INI1
Deficiency, Possessing a High Propensity to
Progress to Secondary INI1-deficient Rhabdoid
Tumors.” Am J Surg Pathol. 2020
Nov;44(11):1459-1468. doi:
10.1097/PAS.0000000000001520. PMID: 33045149
- Nakano Y, Takadera M, Miyazaki M, Qiao Z,
Nakajima K, Noguchi R, Oyama R, Kimura Y,
Okuhiro Y, Yamasaki K, Kunihiro N, Fukushima H,
Inoue T, Hara J, Ozawa T, Kondo T, Ichimura
K. “Drug screening with a novel
tumor-derived cell line identified alternative
therapeutic options for patients with atypical
teratoid/rhabdoid tumor.” Hum Cell. 2021
Jan;34(1):271-278. doi:
10.1007/s13577-020-00438-3. Online ahead of
print. PMID: 32997328
- Nakano Y, Yamasaki K, Satomi K, Fukushima H,
Okuhiro Y, Okada K, Osugi Y, Sakamoto H, Inoue
T, Yoshida A, Ichimura K, Hara J. “A case
of pediatric gliomatosis cerebri harboring H3F3A
K27 mutation.” Pediatr Blood Cancer. 2020
Sep;67(9):e28270. doi: 10.1002/pbc.28270. Epub
2020 Jun 17. PMID: 32965767
- Kanamori M, Takami H, Yamaguchi S, Sasayama T,
Yoshimoto K, Tominaga T, Inoue A, Ikeda N, Kambe
A, Kumabe T, Matsuda M, Tanaka S, Natsumeda M,
Matsuda KI, Nonaka M, Jun K, Yamaoka M, Kagawa
N, Shinojima N, Negoto T, Nakahara Y, Arakawa Y,
Hatazaki S, Shimizu H, Yoshino A, Abe H, Akimoto
J, Kawanishi Y, Suzuki T, Natsume A, Nagane M,
Akiyama Y, Keino D, Fukami T, Tomita T, Kanaya
K, Tokuyama T, Izumoto S, Nakada M, Kuga D,
Yamamoto S, Anei R, Uzuka T, Fukai J, Kijima N,
Terashima K, Ichimura K, Nishikawa R.
“So-called "bifocal tumors" with diabetes
insipidus and negative tumor markers: Are they
all germinoma?” Neuro Oncol. 2021 Feb
25;23(2):295-303. doi:
10.1093/neuonc/noaa199.PMID: 32818237
- Fujimoto K, Shinojima N, Hayashi M, Nakano T,
Ichimura K, Mukasa A. “Histone
deacetylase inhibition enhances the therapeutic
effects of methotrexate on primary central
nervous system lymphoma.” Neurooncol Adv. 2020
Jul 3;2(1):vdaa084. doi: 10.1093/noajnl/vdaa084.
eCollection 2020 Jan-Dec. PMID: 32793886
- Nakano Y, Watanabe Y, Honda-Kitahara M,
Yamagishi Y, Niizuma H, Niihori T, Sasahara Y,
Sonoda Y, Narita Y, Nagane M, Kure S,
Ichimura K. “Utility of a bridged nucleic
acid clamp for liquid biopsy: Detecting BRAF
V600E in the cerebrospinal fluid of a patient
with brain tumor.” Pediatr Blood Cancer. 2020
Oct;67(10):e28651. doi: 10.1002/pbc.28651. PMID:
32776443
- Miki S, Satomi K, Ohno M, Matsushita Y, Kitahara
M, Miyakita Y, Takahashi M, Matsuda M, Ishikawa
E, Matsumura A, Yoshida A, Narita Y, Ichimura
K. “Highly sensitive detection of TERT
promoter mutations in recurrent glioblastomas
using digital PCR.” Brain Tumor Pathol. 2020
Oct;37(4):154-158. doi:
10.1007/s10014-020-00375-x. Epub 2020 Aug 4.
PMID: 32749624
- Ito J, Nakano Y, Shima H, Miwa T, Kogure Y,
Isshiki K, Yamazaki F, Oishi Y, Morimoto Y,
Kataoka K, Okita H, Hirato J, Ichimura K,
Shimada H. “Central nervous system
ganglioneuroblastoma harboring MYO5A-NTRK3
fusion.” Brain Tumor Pathol. 2020
Jul;37(3):105-110. doi:
10.1007/s10014-020-00371-1. PMID: 32556925
- Yamada S, Muto J, De Leon JCA, Kumai T, Ito K,
Murayama K, Hama N, Nakano Y, Satomi K, Arai Y,
Shibata T, Inoue T, Nobusawa S, Ichimura
K, Hirose Y, Abe M. “Primary Spinal
Intramedullary Ewing-like Sarcoma Harboring
CIC-DUX4 Translocation: A Similar Cytological
Appearance as Its Soft Tissue Counterpart but No
Lobulation in Association With Desmoplastic
Stroma” Brain Tumor Pathol. 2020
Jul;37(3):111-117. doi:
10.1007/s10014-020-00366-y. PMID: 32449046
- Takami H, Perry A, Graffeo CS, Giannini C,
Narita Y, Nakazato Y, Saito N, Nishikawa R,
Matsutani M, Ichimura K, Daniels DJ.
“Comparison on epidemiology, tumor location,
histology, and prognosis of intracranial germ
cell tumors between Mayo Clinic and Japanese
consortium cohorts.” J Neurosurg. 2020 Jan
31:1-11. doi: 10.3171/2019.11.JNS191576. PMID:
32005022
- Yamasaki K, Nakano Y, Nobusawa S, Okuhiro Y,
Fukushima H, Inoue T, Murakami C, Hirato J,
Kunihiro N, Matsusaka Y, Honda-Kitahara M, Ozawa
T, Shiraishi K, Kohno T, Ichimura K, Hara
J. “Spinal cord astroblastoma with an
EWSR1-BEND2 fusion classified as a high-grade
neuroepithelial tumour with MN1 alteration.”
Neuropathol Appl Neurobiol. 46(2):190-193, 2020
Dec 21. doi: 10.1111/nan.12593. PMID: 31863478
- Li BK, Vasiljevic A, Dufour C, Yao F, Ho BLB, Lu
M, Hwang EI, Gururangan S, Hansford JR, Fouladi
M, Nobusawa S, Laquerriere A, Delisle MB,
Fangusaro J, Forest F, Toledano H, Solano-Paez
P, Leary S, Birks D, Hoffman LM, Szathmari A,
Faure-Conter C, Fan X, Catchpoole D, Zhou L,
Schultz KAP, Ichimura K, Gauchotte G, Jabado N,
Jones C, Loussouarn D, Mokhtari K, Rousseau A,
Ziegler DS, Tanaka S, Pomeroy SL, Gajjar A,
Ramaswamy V, Hawkins C, Grundy RG, Hill DA,
Bouffet E, Huang A, Jouvet A. “Pineoblastoma
segregates into molecular sub-groups with
distinct clinico-pathologic features: a Rare
Brain Tumor Consortium registry study.” Acta
Neuropathol. 2020 Feb;139(2):223-241. doi:
10.1007/s00401-019-02111-y. PMID: 31820118
- Machida Y, Nakagawa M, Matsunaga H, Yamaguchi M,
Ogawara Y, Shima Y, Yamagata K, Katsumoto T,
Hattori A, Itoh M, Seki T, Nishiya Y, Nakamura
K, Suzuki K, Imaoka T, Baba D, Suzuki M,
Sampetrean O, Saya H, Ichimura K, Kitabayashi I.
“A potent blood-brain barrier-permeable mutant
IDH1 inhibitor suppresses the growth of
glioblastoma with IDH1 mutation in a
patient-derived orthotopic xenograft model.” Mol
Cancer Ther. 2020 Feb;19(2):375-383. doi:
10.1158/1535-7163.MCT-18-1349. PMID: 31727689
2019年
- Fukuma R, Yanagisawa T, Kinoshita M, Shinozaki
T, Arita H, Kawaguchi A, Takahashi M, Narita Y,
Terakawa Y, Tsuyuguchi N, Okita Y, Nonaka M,
Moriuchi S, Takagaki M, Fujimoto Y, Fukai J,
Izumoto S, Ishibashi K, Nakajima Y, Shofuda T,
Kanematsu D, Yoshioka E, Kodama Y, Mano M, Mori
K, Ichimura K, Kanemura Y, Kishima H.
“Prediction of IDH and TERT promoter mutations
in low-grade glioma from magnetic resonance
images using a convolutional neural network.”
Sci Rep. 2019 Dec 30;9(1):20311. doi:
10.1038/s41598-019-56767-3. PMID: 31889117
- Yamasaki K, Nakano Y, Nobusawa S, Okuhiro Y,
Fukushima H, Inoue T, Murakami C, Hirato J,
Kunihiro N, Matsusaka Y, Honda-Kitahara M, Ozawa
T, Shiraishi K, Kohno T, Ichimura K, Hara J.
“Spinal cord astroblastoma with an EWSR1-BEND2
fusion classified as a high-grade
neuroepithelial tumour with MN1 alteration.”
Neuropathol Appl Neurobiol. 2019 Dec 21. doi:
10.1111/nan.12593. [Epub ahead of print] PMID:
31863478
- Guerreiro Stucklin AS, Ryall S, Fukuoka K,
Zapotocky M, Lassaletta A, Li C, Bridge T, Kim
B, Arnoldo A, Kowalski PE, Zhong Y, Johnson M,
Li C, Ramani AK, Siddaway R, Nobre LF, de
Antonellis P, Dunham C, Cheng S, Boué DR,
Finlay JL, Coven SL, de Prada I, Perez-Somarriba
M, Faria CC, Grotzer MA, Rushing E, Sumerauer D,
Zamecnik J, Krskova L, Garcia Ariza M, Cruz O,
Morales La Madrid A, Solano P, Terashima K,
Nakano Y, Ichimura K, Nagane M, Sakamoto H,
Gil-da-Costa MJ, Silva R, Johnston DL, Michaud
J, Wilson B, van Landeghem FKH, Oviedo A,
McNeely PD, Crooks B, Fried I, Zhukova N,
Hansford JR, Nageswararao A, Garzia L, Shago M,
Brudno M, Irwin MS, Bartels U, Ramaswamy V,
Bouffet E, Taylor MD, Tabori U, Hawkins C.
“Alterations in ALK/ROS1/NTRK/MET drive a group
of infantile hemispheric gliomas.” Nat Commun.
2019 Sep 25;10(1):4343. doi:
10.1038/s41467-019-12187-5. PMID: 31554817
- Tsurubuchi T, Nakano Y, Hirato J, Yoshida A,
Muroi A, Sakamoto N, Alexander Z, Matsuda M,
Ishikawa E, Kohno T, Yoshioka T, Honda-Kitahara
M, Ichimura K, Yamamoto T, Matsumura A.
“Subependymal giant cell astrocytoma harboring a
PRRC2B-ALK fusion: A case report.” Pediatr Blood
Cancer. 2019 Dec;66(12):e27995. doi:
10.1002/pbc.27995. PMID: 31502411
- Sakaguchi M, Nakano Y, Honda-Kitahara M,
Kinoshita M, Tanaka S, Oishi M, Noguchi K,
Fukuda M, Maeba H, Watanabe T, Hayashi Y, Ikeda
H, Minato H, Ichimura K, Nojima T, Nakada M.
“Two cases of primary supratentorial
intracranial rhabdomyosarcoma with DICER1
mutation which may belong to a "spindle cell
sarcoma with rhabdomyosarcoma-like feature,
DICER1 mutant".” Brain Tumor Pathol. 2019
Oct;36(4):174-182. doi:
10.1007/s10014-019-00352-z. PMID: 31487013
- Takami H, Fukuoka K, Fukushima S, Nakamura T,
Mukasa A, Saito N, Yanagisawa T, Nakamura H,
Sugiyama K, Kanamori M, Tominaga T, Maehara T,
Nakada M, Kanemura Y, Asai A, Takeshima H,
Hirose Y, Iuchi T, Nagane M, Yoshimoto K,
Matsumura A, Kurozumi K, Nakase H, Sakai K,
Tokuyama T, Shibui S, Nakazato Y, Narita Y,
Nishikawa R, Matsutani M, Ichimura K.
“Integrated Clinical, Histopathological, and
Molecular Data Analysis of 190 Central Nervous
System Germ Cell Tumors from the iGCT
Consortium.” Neuro Oncol. 2019 Dec
17;21(12):1565-1577. doi: 10.1093/neuonc/noz139.
PMID: 31420671
- Fukushima H, Nakano Y, Ishii N, Nozuchi N, Okuno
T, Yamasaki K, Okada K, Fujisaki H, Kunihiro N,
Matsusaka Y, Sakamoto H, Honda-Kitahara M,
Ichimura K, Hara J, Inoue T. “Histological and
genetic analysis of anaplastic pleomorphic
xanthoastrocytoma suspected of malignant
progression over a 12-year clinical course.”
Pathol Int. 2019 Oct;69(10):608-613. doi:
10.1111/pin.12840. PMID: 31397529
- Nakano Y, Hasegawa D, Stewart DR, Schultz KAP,
Harris AK, Hirato J, Uemura S, Tamura A, Saito
A, Kawamura A, Yoshida M, Yamasaki K, Yamashita
S, Ushijima T, Kosaka Y, Ichimura K, Dehner LP,
Hill DA. “Presacral malignant teratoid neoplasm
in association with pathogenic DICER1
variation.” Mod Pathol. 2019
Dec;32(12):1744-1750. doi:
10.1038/s41379-019-0319-4. PMID: 31296931
- Nakano Y, Yamasaki K, Sakamoto H, Matsusaka Y,
Kunihiro N, Fukushima H, Inoue T, Honda-Kitahara
M, Hara J, Yoshida A, Ichimura K. “A long-term
survivor of pediatric midline glioma with H3F3A
K27M and BRAF V600E double mutations.” Brain
Tumor Pathol. 2019 Oct;36(4):162-168. doi:
10.1007/s10014-019-00347-w. PMID: 31254135
- Takami H, Fukushima S, Aoki K, Satomi K, Narumi
K, Hama N, Matsushita Y, Fukuoka K, Yamasaki K,
Nakamura T, Mukasa A, Saito N, Suzuki T,
Yanagisawa T, Nakamura H, Sugiyama K, Tamura K,
Maehara T, Nakada M, Nonaka M, Asai A, Yokogami
K, Takeshima H, Iuchi T, Kanemura Y, Kobayashi
K, Nagane M, Kurozumi K, Yoshimoto K, Matsuda M,
Matsumura A, Hirose Y, Tokuyama T, Kumabe T,
Ueki K, Narita Y, Shibui S, Totoki Y, Shibata T,
Nakazato Y, Nishikawa R, Matsutani M, Ichimura
K; Intracranial Germ Cell Tumor Genome Analysis
Consortium (the iGCT Consortium). “Intratumoural
Immune Cell Landscape in Germinoma Reveals
Multipotent Lineages and Exhibits Prognostic
Significance.” Neuropathol Appl Neurobiol. 2019
Jun 10. doi: 10.1111/nan.12570. [Epub ahead of
print] PMID: 31179566
- Takahashi M, Miki S, Fujimoto K, Fukuoka K,
Matsushita Y, Maida Y, Yasukawa M, Hayashi M,
Shinkyo R, Kikuchi K, Mukasa A, Nishikawa R,
Tamura K, Narita Y, Hamada A, Masutomi K,
Ichimura K. “Eribulin penetrates brain tumor
tissue and prolongs survival of mice harboring
intracerebral glioblastoma xenografts.” Cancer
Sci. 2019 Jul;110(7):2247-2257. doi:
10.1111/cas.14067. Epub 2019 Jun 10.
- Kurozumi K, Nakano Y, Ishida J, Tanaka T, Doi M,
Hirato J, Yoshida A, Washio K, Shimada A, Kohno
T, Ichimura K, Yanai H, Date I. “High-grade
glioneuronal tumor with an ARHGEF2-NTRK1 fusion
gene.” Brain Tumor Pathol. 2019
Jul;36(3):121-128. doi:
10.1007/s10014-019-00345-y. PMID: 31011918
- Tateishi K, Nakamura T, Juratli TA, Williams EA,
Matsushita Y, Miyake S, Nishi M, Miller JJ,
Tummala SS, Fink AL, Lelic N, Koerner MVA,
Miyake Y, Sasame J, Fujimoto K, Tanaka T,
Minamimoto R, Matsunaga S, Mukaihara S, Shuto T,
Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S,
Curry WT, Dias-Santagata D, Yamamoto T, Ichimura
K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H,
Cahill DP. “PI3K/AKT/mTOR Pathway Alterations
Promote Malignant Progression and Xenograft
Formation in Oligodendroglial Tumors.” Clin
Cancer Res. 2019 Jul 15;25(14):4375-4387. doi:
10.1158/1078-0432.CCR-18-4144. Epub 2019 Apr 11.
PMID: 30975663
- Sasaki A, Hirato J, Hirose T, Fukuoka K,
Kanemura Y, Hashimoto N, Kodama Y, Ichimura K,
Sakamoto H, Nishikawa R. “Review of ependymomas:
assessment of consensus in pathological
diagnosis and correlations with genetic profiles
and outcome.” Brain Tumor Pathol. Brain Tumor
Pathol. 2019 Apr;36(2):92-101. doi:
10.1007/s10014-019-00338-x. Epub 2019 Mar 30.
PMID: 30929114
- Nakamura T, Fukuoka K, Nakano Y, Yamasaki K,
Matsushita Y, Yamashita S, Ikeda J, Udaka N,
Tanoshima R, Shiba N, Tateishi K, Yamanaka S,
Yamamoto T, Hirato J, Ichimura K. “Genome-wide
DNA methylation profiling shows molecular
heterogeneity of anaplastic pleomorphic
xanthoastrocytoma.” Cancer Sci. 110(2):828-832,
2019. doi: 10.1111/cas.13903.
2018年
- Fukuoka K, Kanemura Y, Shofuda T, Fukushima S,
Yamashita S, Narushima D, Kato M, Honda-Kitahara
M, Ichikawa H, Kohno T, Sasaki A, Hirato J,
Hirose T, Komori T, Satomi K, Yoshida A,
Yamasaki K, Nakano Y, Takada A, Nakamura T,
Takami H, Matsushita Y, Suzuki T, Nakamura H,
Makino K, Sonoda Y, Saito R, Tominaga T,
Matsusaka Y, Kobayashi K, Nagane M, Furuta T,
Nakada M, Narita Y, Hirose Y, Ohba S, Wada A,
Shimizu K, Kurozumi K, Date I, Fukai J, Miyairi
Y, Kagawa N, Kawamura A, Yoshida M, Nishida N,
Wataya T, Yamaoka M, Tsuyuguchi N, Uda T,
Takahashi M, Nakano Y, Akai T, Izumoto S, Nonaka
M, Yoshifuji K, Kodama Y, Mano M, Ozawa T,
Ramaswamy V, Taylor MD, Ushijima T, Shibui S,
Yamasaki M, Arai H, Sakamoto H, Nishikawa R,
Ichimura K; Japan Pediatric Molecular
Neuro-Oncology Group (JPMNG). “Significance of
molecular classification of ependymomas:
C11orf95-RELA fusion-negative supratentorial
ependymomas are a heterogeneous group of
tumors.” Acta Neuropathol Commun. 2018 Dec
4;6(1):134. doi: 10.1186/s40478-018-0630-1.
- Nakano Y, Tomiyama A, Kohno T, Yoshida A,
Yamasaki K, Ozawa T, Fukuoka K, Fukushima H,
Inoue T, Hara J, Sakamoto H, Ichimura K.
“Identification of a novel KLC1-ROS1 fusion in a
case of pediatric low-grade localized glioma.”
Brain Tumor Pathol. 36(1):14-19, 2019. doi:
10.1007/s10014-018-0330-3.
- Yoshida A, Satomi K, Ohno M, Matsushita Y,
Takahashi M, Miyakita Y, Hiraoka N, Narita Y,
Ichimura K. “Frequent False-Negative
Immunohistochemical Staining with IDH1
(R132H)-Specific H09 Antibody on Frozen Section
Control Slides: a Potential Pitfall in Glioma
Diagnosis.” Histopathology. 74(2):350-354, 2019.
doi: 10.1111/his.13756.
- Arita H, Kinoshita M, Kawaguchi A, Takahashi M,
Narita Y, Terakawa Y, Tsuyuguchi N, Okita Y,
Nonaka M, Moriuchi S, Takagaki M, Fujimoto Y,
Fukai J, Izumoto S, Ishibashi K, Nakajima Y,
Shofuda T, Kanematsu D, Yoshioka E, Kodama Y,
Mano M, Mori K, Ichimura K, Kanemura Y. “Lesion
location implemented magnetic resonance imaging
radiomics for predicting IDH and TERT promoter
mutations in grade II/III gliomas.” Sci Rep.
2018 Aug 6;8(1):11773. doi:
10.1038/s41598-018-30273-4.
- Yamamoto Y, Sasaki N, Kumagai K, Takeuchi S,
Toyooka T, Otani N, Wada K, Narita Y, Ichimura
K, Namba H, Mori K, Tomiyama A. “Involvement of
Intracellular Cholesterol in
Temozolomide-Induced Glioblastoma Cell Death.”
Neurol Med Chir (Tokyo). 58(7):296-302, 2018 Jun
13. doi: 10.2176/nmc.ra.2018-0040. PMID:
29899179
- Miki S, Imamichi S, Fujimori H, Tomiyama A,
Fujimoto K, Satomi K, Matsushita Y, Matsuzaki S,
Takahashi M, Ishikawa E, Yamamoto T, Matsumura
A, Mukasa A, Nishikawa R, Masutomi K, Narita Y,
Masutani M and Ichimura K. Concomitant
administration of radiation with eribulin
improves the survival of mice harboring
intracerebral glioblastoma. Cancer Sci. 2018 May
14. doi: 10.1111/cas.13637. [Epub ahead of
print]
- Otani R, Uzuka T, Higuchi F, Matsuda H, Nomura
M, Tanaka S, Mukasa A, Ichimura K, Kim P, Ueki
K. “IDH-mutated astrocytomas with 19q-loss
constitute a subgroup that confers better
prognosis.” Cancer Sci. 2018 May 12. doi:
10.1111/cas.13635. [Epub ahead of print]
- Miyazaki M, Otomo R, Matsushima-Hibiya Y, Suzuki
H, Nakajima A, Abe N, Tomiyama A, Ichimura K,
Matsuda K, Watanabe T, Ochiya T, Nakagama H,
Sakai R, Enari M. "The p53 activator overcomes
resistance to ALK inhibitors by regulating
p53-target selectivity in ALK-driven
neuroblastomas”, Cell Death Discov 2018 doi:
10.1038/s41420-018-0059-0
- Masui K, Komori T, Kato Y, Masutomi K, Ichimura
K, Ogasawara S, Kaneko MK, Oki H, Suzuki H,
Nitta M, Maruyama T, Muragaki Y, Kawamata T,
Sawada T, Shibata N. “Elevated TERT Expression
in TERT-Wildtype Adult Diffuse Gliomas:
Histological Evaluation with a Novel
TERT-Specific Antibody.” Biomed Res Int. 2018
Mar 5;2018:7945845.
- Shimoi T, Yoshida M, Kitamura Y, Yoshino T,
Kawachi A, Shimomura A, Noguchi E, Yunokawa M,
Yonemori K, Shimizu C, Kinoshita T, Ichimura K,
Fukuda T, Fujiwara Y, Tamura K. “TERT promoter
hotspot mutations in breast cancer.” Breast
Cancer 2017 Dec 8. doi:
10.1007/s12282-017-0825-5. [Epub ahead of print]
- Yamamoto Y, Tomiyama A, Sasaki N, Yamaguchi H,
Shirakihara T, Nakashima K, Kumagai K, Takeuchi
S, Toyooka T, Otani N, Wada K, Narita Y,
Ichimura K, Sakai R, Namba H, Mori K.
“Intracellular cholesterol level regulates
sensitivity of glioblastoma cells against
temozolomide-induced cell death by modulation of
caspase-8 activation via death receptor
5-accumulation and activation in the plasma
membrane lipid raft.” Biochem Biophys Res
Commun. 495:1292-1299, 2018
- Onishi S, Yamasaki F, Nakano Y, Takayasu T,
Amatya VJ, Kolakshyapati M, Takeshima Y, Hirose
T, Ichimura K, Sugiyama K, Kurisu K. “RELA
fusion-positive anaplastic ependymoma: molecular
characterization and advanced MR imaging.” Brain
Tumor Pathol 35(1):41-45, 2018
2017年
- Morita S, Nitta M, Muragaki Y, Komori T, Masui
K, Maruyama T, Ichimura K, Nakano Y, Sawada T,
Koriyama S, Tsuzuki S, Yasuda T, Hashimoto K,
Niwa A, Kawamata T. “Brainstem pilocytic
astrocytoma with H3 K27M mutation: case report.”
J Neurosurg 2017 [Epub ahead of print]
- Nomura M, Mukasa A, Nagae G, Yamamoto S, Tatsuno
K, Ueda H, Fukuda S, Umeda T, Suzuki T, Otani R,
Kobayashi K, Maruyama T, Tanaka S, Takayanagi S,
Nejo T, Takahashi S, Ichimura K, Nakamura T,
Muragaki Y, Narita Y, Nagane M, Ueki K,
Nishikawa R, Shibahara J, Aburatani H, Saito N.
“Distinct molecular profile of diffuse
cerebellar gliomas.” Acta Neuropathol
134(6):941-956, 2017
- Nakamura T, Fukuoka K, Ikeda J, Yoshitomi M,
Udaka N, Tanoshima R, Tateishi K, Yamanaka S,
Ichimura K, Yamamoto T. “Encouraging option of
multi-staged gross total resection for a
C11orf-RelA fusion-positive supratentorial
anaplastic ependymoma.” Brain Tumor Pathol.
34(4):160-164, 2017
- Takayanagi S, Mukasa A, Tanaka S, Nomura M,
Omata M, Yanagisawa S, Yamamoto S, Ichimura K,
Nakatomi H, Ueki K, Aburatani H, Saito N.
“Differences in genetic and epigenetic
alterations between von Hippel-Lindau
disease-related and sporadic hemangioblastomas
of the central nervous system.” Neuro Oncol 2017
[Epub ahead of print]
- Fukushima S, Yamashita S, Kobayashi H, Takami H,
Fukuoka K, Nakamura T, Yamasaki K, Matsushita Y,
Nakamura H, Totoki Y, Kato M, Suzuki T, Mishima
K, Yanagisawa T, Mukasa A, Saito N, Kanamori M,
Kumabe T, Tominaga T, Nagane M, Iuchi T,
Yoshimoto K, Mizoguchi M, Tamura K, Sakai K,
Sugiyama K, Nakada M, Yokogami K, Takeshima H,
Kanemura Y, Matsuda M, Matsumura A, Kurozumi K,
Ueki K, Nonaka M, Asai A, Kawahara N, Hirose Y,
Takayama T, Nakazato Y, Narita Y, Shibata T,
Matsutani M, Ushijima T, Nishikawa R, Ichimura
K; Intracranial Germ Cell Tumor Genome Analysis
Consortium (The iGCTConsortium). “Genome-wide
methylation profiles in primary intracranial
germ cell tumors indicate a primordial germ cell
origin for germinomas.” Acta Neuropathol
133(3):445-462, 2017
- Nakamura T, Yamashita S, Fukumura K, Nakabayashi
J, Tanaka K, Tamura K, Tateishi K, Kinoshita M,
Fukushima S, Takami H, Fukuoka K, Yamazaki K,
Matsushita Y, Ohno M, Miyakita Y, Shibui S, Kubo
A, Shuto T, Kocialkowski S, Yamanaka S, Mukasa
A, Sasayama T, Mishima K, Maehara T, Kawahara N,
Nagane M, Narita Y, Mano H, Ushijima T, Ichimura
K. “Genome-wide DNA methylation profiling
identifies primary central nervous system
lymphoma as a distinct entity different from
systemic diffuse large B-cell lymphoma.” Acta
Neuropathol 133(2):321-324, 2017
- Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt
H, Smith A, Hansford JR, von Hoff K, Wright KD,
Hwang E, Frappaz D, Kanemura Y, Massimino M,
Faure-Conter C, Modena P, Tabori U, Warren KE,
Holland EC, Ichimura K, Giangaspero F, Castel D,
von Deimling A, Kool M, Dirks PB, Grundy RG,
Foreman NK, Gajjar A, Korshunov A, Finlay J,
Gilbertson RJ, Ellison DW, Aldape KD, Merchant
TE, Bouffet E, Pfister SM, Taylor MD. “The
current consensus on the clinical management of
intracranial ependymoma and its distinct
molecular variants.” Acta Neuropathol
133(1):5-12, 2017
2016年
- Arita H, Yamasaki K, Matsushita Y, Nakamura T,
Shimokawa A, Takami H, Tanaka S, Mukasa A,
Shirahata M, Shimizu S, Suzuki K, Saito K,
Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura
K, Sumita K, Ohno M, Miyakita Y, Kagawa N,
Hashimoto N, Hatae R, Yoshimoto K, Shinojima N,
Nakamura H, Kanemura Y, Okita Y, Kinoshita M,
Ishibashi K, Shofuda T, Kodama Y, Mori K,
Tomogane Y, Fukai J, Fujita K, Terakawa Y,
Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H,
Shibuya M, Maehara T, Saito N, Nagane M,
Kawahara N, Ueki K, Yoshimine T, Miyaoka E,
Nishikawa R, Komori T, Narita Y, Ichimura K. “A
combination of TERT promoter mutation and MGMT
methylation status predicts clinically relevant
subgroups of newly diagnosed glioblastomas.”
Acta Neuropathol Commun 4:79, 2016.
- Ichimura K, Fukushima S, Totoki Y, Matsushita Y,
Otsuka A, Tomiyama A, Niwa T, Takami H, Nakamura
T, Suzuki T, Fukuoka K, Yanagisawa T, Mishima K,
Nakazato Y, Hosoda F, Narita Y, Shibui S,
Yoshida A, Mukasa A, Saito N, Kumabe T, Kanamori
M, Tominaga T, Kobayashi K, Shimizu S, Nagane M,
Iuchi T, Mizoguchi M, Yoshimoto K, Tamura K,
Maehara T, Sugiyama K, Nakada M, Sakai K,
Kanemura Y, Nonaka M, Asai A, Yokogami K,
Takeshima H, Kawahara N, Takayama T, Yao M, Kato
M, Nakamura H, Hama N, Sakai R, Ushijima T,
Matsutani M, Shibata T, Nishikawa R;
Intracranial Germ Cell Tumor Genome Analysis
Consortium. “Recurrent neomorphic mutations of
MTOR in central nervous system and testicular
germ cell tumors may be targeted for therapy.”
Acta Neuropathol 131:889-901, 2016
- Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E,
Soda M, Ueda H, Yasuda T, Yamaguchi H, Lee JH,
Shishido-Hara Y, Sasaki A, Shirahata M, Mishima
K, Ichimura K, Mukasa A, Narita Y, Saito N,
Aburatani H, Nishikawa R, Nagane M, Mano H.
“Genomic characterization of primary central
nervous system lymphoma” Acta Neuropathol
131:865-875, 2016
- Ohno M, Narita Y, Miyakita Y, Matsushita Y,
Arita H, Yonezawa M, Yoshida A, Fukushima S,
Takami H, Ichimura K, Shibui S. “Glioblastomas
with IDH1/2 mutations have a short clinical
history and have a favourable clinical outcome.”
Jpn J Clin Oncol 46:31-39, 2016
- Komori K, Yanagisawa R, Miyairi Y, Sakashita K,
Shiohara M, Fujihara I, Morita D, Nakamura T,
Ogiso Y, Sano K, Shirahata M, Fukuoka K,
Ichimura K, Shigeta H. “Temozolomide treatment
for pediatric refractory anaplastic ependymoma
with low MGMT protein expression.” Pediatr Blood
Cancer 63:152-155, 2016
- Nakamura T, Tateishi K, Niwa T, Matsushita Y,
Tamura K, Kinoshita M, Tanaka K, Fukushima S,
Takami H, Arita H, Kubo A, Shuto T, Ohno M,
Miyakita Y, Kocialkowski S, Sasayama T,
Hashimoto N, Maehara T, Shibui S, Ushijima T,
Kawahara N, Narita Y, Ichimura K. “Recurrent
mutations of CD79B and MYD88 are the hallmark of
primary central nervous system lymphomas.”
Neuropathol Appl Neurobiol 42:279-90, 2016
|
| |
|
|
|
|
|
|
各研究分野紹介一覧